SCHEMBL6020973

SCHEMBL6020973

CCOC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)N(C)C#N

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 1/20 0.55
MMP8 P22894 1/20 0.55
MMP14 P50281 1/20 0.55
CTSL P07711 2/20 0.54
CTSS P25774 1/20 0.54
CTSK P43235 1/20 0.54
TACR1 P25103 5/20 0.52
MAPT P10636 4/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NMBR P28336 7/20 0.52
CCKBR P32239 1/20 0.52
GAA P10253 1/20 0.52
HTT P42858 1/20 0.52
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
THRB P10828 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6019709 0.91 CTSL (0.55) MMP9MMP8MMP14CTSLCTSS
SCHEMBL6019223 0.91 MMP9 (0.58) MMP9MMP8MMP14CTSLCTSS
SCHEMBL6020520 0.91 CCKBR (0.55) MMP9MMP8MMP14CTSLCTSS
SCHEMBL6020369 0.90 NMBR (0.65) MMP9MMP8MMP14CTSLCTSS
SCHEMBL6019319 0.90 CTSL (0.54) MMP9MMP8MMP14CTSLCTSS
SCHEMBL6020814 0.89 CCKBR (0.56) MMP9MMP8MMP14CTSLCTSS
SCHEMBL6021514 0.87 CTSL (0.71) MMP9MMP8MMP14CTSLCTSS
SCHEMBL6020424 0.87 NMBR (0.52) MMP9MMP8MMP14CTSLCTSS
SCHEMBL6020252 0.85 MMP9 (0.48) MMP9MMP8MMP14CTSLCTSS
SCHEMBL6023409 0.85 MMP9 (0.61) MMP9MMP8MMP14CTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US claimed
EP-1575903-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES Jerini AG (DE) 2005-09-21 EP claimed
WO-2004065353-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES JERINI AG (DE) 2004-08-05 WO claimed
WO-2004056755-A2 COMPOUNDS FOR THE INHIBITION OF NON-PROTEOLYTIC ENZYMES JERENI AG (DE) 2004-07-08 WO claimed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP claimed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP claimed
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US disclosed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP disclosed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252813-A1 Apparatus for curing a composite laminate DHX29, HDHD5, DHRS9 MMP9 2430/4885MMP8 2383/4885MMP14 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.